FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileLycia Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
LYCA
Lycia Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Lycia Therapeutics Inc. (LYCA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLYCA
LYCA
Lycia Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
LYCA
  1. Home
  2. Stocks
  3. Lycia Therapeutics Inc.
LT

Lycia Therapeutics Inc.

🇺🇸LYCA•NASDAQ
LT

Lycia Therapeutics Inc.

🇺🇸LYCA•NASDAQ
Market cap
$1.81B
Sentiment

Your view on LYCA

Mkt Cap
$1.81B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Lycia Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Aetna Wun Trombley
Headquarters
400 East Jamie Court, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Aetna Wun Trombley
Headquarters
400 East Jamie Court, South San Francisco, CA, US
Description

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases.

The company was founded in 2019 and is headquartered in South San Francisco, CA.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Lycia Therapeutics Inc. from FRC's valuation model, read against the market price. LYCA last traded at $31.35; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Lycia Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Lycia Therapeutics Inc.. Lycia Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Lycia Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 19, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$50.00

average of analysts' targets

 

$50.00

Low $50.00

Median $50.00

High $50.00

 

Recent analyst actions1 rating and price-target change, latest Nov 17, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Lycia Therapeutics Inc.. Lycia Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold LYCA12 companies · 5 funds

More Biotechnology companies

Market cap

  • NKTXNkarta, Inc.NASDAQ$82M
  • NMADNOMAD Power Solutions, Inc.NASDAQ$35M
  • NMLSFRestart Life Sciences Corp.OTC$4M
  • NMRANeumora Therapeutics, Inc. Common StockNASDAQ$69M
  • NMTRQ9 Meters Biopharma, Inc.OTC$7,230
  • NNBPNanobac Pharmaceuticals, IncorporatedOTC$24,951
  • NNLXNanoLogix, Inc.OTC$11,961
  • NNVCNanoViricides, Inc.AMEX$30M
  • NOX.AXNoxopharm LimitedASX
  • NRIXNurix Therapeutics, Inc.NASDAQ$1.5B
  • NRSNNeuroSense Therapeutics Ltd.NASDAQ$3M
  • NRSNWNeuroSense Therapeutics Ltd.NASDAQ$135,667

ETFs holding Lycia Therapeutics Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
  • VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%

Largest holders first, then the funds most concentrated in LYCA.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Lycia Therapeutics Inc., and how their positions are changing. At a $1.81B market value, institutional positions materially move Lycia Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Lycia Therapeutics Inc. executives and directors. Shares of Lycia Therapeutics Inc. have traded between $22.19 and $36.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Lycia Therapeutics Inc.. Lycia Therapeutics Inc. is a $1.81B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Lycia Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Lycia Therapeutics Inc.. Coverage tracks Lycia Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Lycia Therapeutics Inc.

LYCA Analysis
Weak
Past2
Growth1
Health1
Profit1
Value1

News

Latest Market News